Pediatric Immune Thrombocytopenia: The Impact of Antithyroid Antibodies on the Treatment Outcomes

• Published in: Clinical pediatrics 2025-02, Vol.64 (2), p.264-270
• Main Authors: Skoric, Dejan, Krcunovic, Jelena, Svorcan, Jovana, Krstovski, Nada, Rodic, Predrag, Lazic, Jelena, Milosevic, Goran, Rajic, Vladan, Mitrovic, Jadranka
• Format: Article
• Language: English
• Subjects: Adolescent; Antibodies; Autoantibodies; Autoantibodies - blood; Autoimmune diseases; Child; Child, Preschool; Clinical outcomes; Cross-Sectional Studies; Female; Homeostasis; Humans; Idiopathic thrombocytopenic purpura; Infant; Iodide peroxidase; Male; Pathogenesis; Patients; Pediatrics; Population studies; Prevalence; Purpura; Purpura, Thrombocytopenic, Idiopathic - blood; Purpura, Thrombocytopenic, Idiopathic - immunology; Thyroglobulin; Treatment Outcome
• ISSN: 0009-9228; 1938-2707; 1938-2707
• DOI: 10.1177/00099228241262173

Immune thrombocytopenic purpura (ITP) is an acquired immune-mediated bleeding disorder characterized by isolated low platelet (PLT) counts. Immune thrombocytopenic purpura pathogenesis involves multiple immune mechanisms causing PLT destruction and inadequate production. Owing to impaired immune homeostasis, ITP patients can develop other than anti-PLT autoantibodies even in the absence of clinical signs of autoimmune disease, such as anti-thyroglobulin (TG) and anti-thyroperoxidase (TPO) antibodies. Our objective is to determine the prevalence of antithyroid antibodies (ATAs) in the population of pediatric ITP patients, and the differences in ATA positivity prevalence in newly diagnosed/persistent ITP, and chronic ITP patient subgroups, as well as to establish the impact of ATA positivity on the treatment outcomes. A cross-sectional observational study was conducted involving 75 pediatric patients diagnosed with ITP and 60 healthy controls, carried out over a period of 11 years. The prevalence of ATA was significantly higher in ITP patients compared with controls (28% vs 5%, P < .05). Initial PLT count was significantly lower in ATA-positive patients, but the treatment response did not differ between ATA-positive and ATA-negative patients. To conclude, our study confirmed that ITP patients have a higher prevalence of ATA compared with the healthy pediatric population; however, no association was found between ATA positivity and disease duration or treatment outcomes. Our findings suggest that ATA screening may not be prognostic for ITP in pediatric population, but further research with larger cohorts may be beneficial to elucidate the role of ATA in ITP pathogenesis and management.